<DOC>
	<DOCNO>NCT00309998</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vinorelbine , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving vinorelbine together bevacizumab may kill tumor cell . PURPOSE : This phase II trial study well give vinorelbine together bevacizumab work treat old patient stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Vinorelbine Bevacizumab Treating Older Patients With Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate median time disease progression old patient non-squamous stage IIIB stage IV non-small cell lung cancer ( NSCLC ) treat vinorelbine ditartate bevacizumab . Secondary - Estimate response rate patient treat regimen . - Estimate median survival patient treat regimen . - Evaluate safety combination vinorelbine ditartate bevacizumab old patient . OUTLINE : This open-label study . Patients receive vinorelbine ditartate IV 6 10 minute day 1 8 bevacizumab IV 30-90 minute day 1 . Treatment repeat every 21 day absence unacceptable toxicity disease progression . After completion study therapy , patient follow periodically . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsquamous , nonsmall cell lung cancer ( NSCLC ) Stage IIIB ( T , N3 , M0 OR T4 , N , M0 , OR pleural effusion ) OR stage IV ( T , N , M1 ) disease Mixed tumor categorize predominant cell type unless small cell element present , case patient ineligible Measurable evaluable disease No lung carcinoma squamous cell histology histology close proximity major vessel cavitation No known brain metastasis , even treat PATIENT CHARACTERISTICS : No malignancy within past 5 year except nonmelanoma skin cancer ECOG performance status 01 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 mg/dL Transaminases ≤ 5 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN Urine protein : creatinine ratio &lt; 1 INR ≤ 1.5 PTT normal No prior ileus neuropathy compromise use vinorelbine ditartate Patients history hypertension must well control ( blood pressure &lt; 150/100 mm Hg ) stable regimen antihypertensive therapy None follow condition : Unstable angina New York Heart Association grade IIIV congestive heart failure Myocardial infarction within past 6 month Stroke within past 6 month Evidence bleed diathesis coagulopathy Clinically significant peripheral vascular disease Serious , nonhealing wound , ulcer , bone fracture History hemoptysis ( bright red blood ≥ ½ teaspoon ) No significant traumatic injury within past 4 week No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior chemotherapy NSCLC More 4 week since prior concurrent participation another experimental drug study More 4 week since prior immunotherapy , hormonal therapy , radiotherapy recover More 28 day since prior major surgical procedure open biopsy No anticipation need major surgery course trial More 7 day since prior minor surgical procedure ( e.g. , fineneedle aspiration core biopsy ) No concurrent fulldose anticoagulation therapy thromboembolic disease , aspirin ( &gt; 325 mg/day ) , nonsteroidal antiinflammatory drug</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>